HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

S 5682

a purified flavonoid fraction composed of 90% diosmin 7-rhamnoglucoside and 10% hesperidin 7-rhamnoglucoside

Also Known As:

Arvenum 500; Capiven; Detralex; S-5682; S5682; Venitol

Networked: 26 relevant articles (3 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Bogachev, V Iu: 3 articles (01/2021 - 01/2006)
2.	Boldin, B V: 3 articles (01/2021 - 01/2016)
3.	Samenkov, A Iu: 2 articles (01/2021 - 01/2020)
4.	Turkin, P Iu: 2 articles (01/2021 - 01/2020)
5.	Rovenská, Emília: 2 articles (09/2009 - 05/2008)
6.	Rovenský, Jozef: 2 articles (09/2009 - 05/2008)
7.	Stancíková, Mária: 2 articles (09/2009 - 05/2008)
8.	Stvrtinová, Viera: 2 articles (09/2009 - 05/2008)
9.	Svík, Karol: 2 articles (09/2009 - 05/2008)
10.	Sapelkin, S V: 2 articles (01/2008 - 01/2006)

Related Diseases

1.	Ischemia 05/01/1997 - "At reperfusion, after thirty minutes of ischemia, S 5682 significantly decreased the observed macromolecular permeability (103.6 +/- 15.4 versus 42.6 +/- 9.3 leaks/cm2; P < 0.01). " 05/01/1997 - "The authors also investigated the effects of S 5682 on macromolecular permeability increase and leukocyte adhesion during ischemia-reperfusion by using the same preparation. " 01/01/1997 - "Thus, it seemed of interest to evaluate the effects of S-5682 on ischemia/reperfusion, ie, the changes in mean internal diameter and blood flow of arterioles and venules and the functional capillary density (FCD) during reperfusion after ninety minutes of total ischemia in the hamster cheek pouch microvasculature. " 11/01/1995 - "At reperfusion, after 30 min ischemia, S 5682 significantly decreased the observed macromolecular permeability (168.5 +/- 19.7 vs. 52.7 +/- 6.3 leaks/cm2; p < 0.01). " 11/01/1995 - "We also investigated the effects of S 5682 on macro- molecular permeability increase and leukocyte adhesion during ischemia-reperfusion using the same preparation. "
2.	Purpura 03/01/1993 - "This resulted in a significant improvement of symptoms of capillary fragility (spontaneous ecchymosis, epistaxis, purpura, petechiae, gingivorrhagia, metrorrhagia and conjunctival haemorrhage) in S 5682 treated patients (p < 0.001). "
3.	Metrorrhagia (Spotting) 03/01/1993 - "This resulted in a significant improvement of symptoms of capillary fragility (spontaneous ecchymosis, epistaxis, purpura, petechiae, gingivorrhagia, metrorrhagia and conjunctival haemorrhage) in S 5682 treated patients (p < 0.001). "
4.	Epistaxis (Nosebleed) 03/01/1993 - "This resulted in a significant improvement of symptoms of capillary fragility (spontaneous ecchymosis, epistaxis, purpura, petechiae, gingivorrhagia, metrorrhagia and conjunctival haemorrhage) in S 5682 treated patients (p < 0.001). "
5.	Ecchymosis 03/01/1993 - "This resulted in a significant improvement of symptoms of capillary fragility (spontaneous ecchymosis, epistaxis, purpura, petechiae, gingivorrhagia, metrorrhagia and conjunctival haemorrhage) in S 5682 treated patients (p < 0.001). "

Related Drugs and Biologics

1.	Oxidants (Oxidizing Agents)
2.	Histamine (Histamine Dihydrochloride)
3.	Leukotriene B4
4.	Bradykinin
5.	Flavonoids
6.	Diosmin (Daflon)
7.	Methotrexate (Mexate)
8.	Hesperidin
9.	Analgesics (Analgesic Drugs)
10.	Therapeutic Uses

Related Therapies and Procedures

1.	Oral Administration
2.	Drug Therapy (Chemotherapy)
3.	Hemorrhoidectomy
4.	Therapeutics
5.	Intravenous Injections